A Case of cutaneous large B-cell lymphoma during treatment of multiple sclerosis with fingolimod

Derek W. Stitt, Christopher J. Boes, Eoin Flanagan, Matthew T. Howard, Joseph P. Colgan

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The authors report a case of a 69-year-old woman with multiple sclerosis treated with fingolimod for duration of over one year who subsequently developed cutaneous large B cell lymphoma. There are few reported cases of lymphoma associated with fingolimod treatment for multiple sclerosis, but rates are higher than expected in the general population. The authors hope to promote awareness of the potential risk of this medication so that more diligent disease surveillance can be performed by both prescribing practitioners of fingolimod and their patients who receive it.

Original languageEnglish (US)
Pages (from-to)115-117
Number of pages3
JournalMultiple Sclerosis and Related Disorders
Volume19
DOIs
StatePublished - Jan 1 2018

Fingerprint

B-Cell Lymphoma
Multiple Sclerosis
Skin
Lymphoma
Therapeutics
Population
Fingolimod Hydrochloride

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

A Case of cutaneous large B-cell lymphoma during treatment of multiple sclerosis with fingolimod. / Stitt, Derek W.; Boes, Christopher J.; Flanagan, Eoin; Howard, Matthew T.; Colgan, Joseph P.

In: Multiple Sclerosis and Related Disorders, Vol. 19, 01.01.2018, p. 115-117.

Research output: Contribution to journalArticle

Stitt, Derek W. ; Boes, Christopher J. ; Flanagan, Eoin ; Howard, Matthew T. ; Colgan, Joseph P. / A Case of cutaneous large B-cell lymphoma during treatment of multiple sclerosis with fingolimod. In: Multiple Sclerosis and Related Disorders. 2018 ; Vol. 19. pp. 115-117.
@article{d07500b4a0fa4af3b6842c6347f1eff7,
title = "A Case of cutaneous large B-cell lymphoma during treatment of multiple sclerosis with fingolimod",
abstract = "The authors report a case of a 69-year-old woman with multiple sclerosis treated with fingolimod for duration of over one year who subsequently developed cutaneous large B cell lymphoma. There are few reported cases of lymphoma associated with fingolimod treatment for multiple sclerosis, but rates are higher than expected in the general population. The authors hope to promote awareness of the potential risk of this medication so that more diligent disease surveillance can be performed by both prescribing practitioners of fingolimod and their patients who receive it.",
author = "Stitt, {Derek W.} and Boes, {Christopher J.} and Eoin Flanagan and Howard, {Matthew T.} and Colgan, {Joseph P.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.msard.2017.11.014",
language = "English (US)",
volume = "19",
pages = "115--117",
journal = "Multiple Sclerosis and Related Disorders",
issn = "2211-0348",
publisher = "Elsevier",

}

TY - JOUR

T1 - A Case of cutaneous large B-cell lymphoma during treatment of multiple sclerosis with fingolimod

AU - Stitt, Derek W.

AU - Boes, Christopher J.

AU - Flanagan, Eoin

AU - Howard, Matthew T.

AU - Colgan, Joseph P.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - The authors report a case of a 69-year-old woman with multiple sclerosis treated with fingolimod for duration of over one year who subsequently developed cutaneous large B cell lymphoma. There are few reported cases of lymphoma associated with fingolimod treatment for multiple sclerosis, but rates are higher than expected in the general population. The authors hope to promote awareness of the potential risk of this medication so that more diligent disease surveillance can be performed by both prescribing practitioners of fingolimod and their patients who receive it.

AB - The authors report a case of a 69-year-old woman with multiple sclerosis treated with fingolimod for duration of over one year who subsequently developed cutaneous large B cell lymphoma. There are few reported cases of lymphoma associated with fingolimod treatment for multiple sclerosis, but rates are higher than expected in the general population. The authors hope to promote awareness of the potential risk of this medication so that more diligent disease surveillance can be performed by both prescribing practitioners of fingolimod and their patients who receive it.

UR - http://www.scopus.com/inward/record.url?scp=85035004316&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85035004316&partnerID=8YFLogxK

U2 - 10.1016/j.msard.2017.11.014

DO - 10.1016/j.msard.2017.11.014

M3 - Article

C2 - 29190574

AN - SCOPUS:85035004316

VL - 19

SP - 115

EP - 117

JO - Multiple Sclerosis and Related Disorders

JF - Multiple Sclerosis and Related Disorders

SN - 2211-0348

ER -